Summit Rock Advisors, LP Day One Biopharmaceuticals, Inc. Transaction History
Summit Rock Advisors, LP
- $312 Million
- Q1 2024
A detailed history of Summit Rock Advisors, LP transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Summit Rock Advisors, LP holds 51,502 shares of DAWN stock, worth $765,834. This represents 0.27% of its overall portfolio holdings.
Number of Shares
51,502Holding current value
$765,834% of portfolio
0.27%Shares
3 transactions
Others Institutions Holding DAWN
# of Institutions
148Shares Held
60MCall Options Held
47.7KPut Options Held
61.3K-
Atlas Venture Life Science Advisors, LLC6.43MShares$95.6 Million13.29% of portfolio
-
Black Rock Inc. New York, NY5.03MShares$74.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.77MShares$71 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.81MShares$56.6 Million0.02% of portfolio
-
State Street Corp Boston, MA2.89MShares$43 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1.09B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...